Research articleSarsasapogenin (cas 126-19-2) reverses depressive-like behaviors and nicotinic acetylcholine receptors induced by olfactory bulbectomy

Add time:09/24/2019    Source:sciencedirect.com

Cholinergic signalling in the hippocampus may contribute to the aetiology of mood regulation. Antidepressants can reverse the increase in acetylcholinesterase (AChE) activity induced by olfactory bulbectomy. The activation of nicotinic acetylcholine receptors (nAChRs) also alleviates the symptoms of depression. This study advances the development of sarsasapogenin, which interacts with cholinergic signalling and has a favourable antidepressant profile in olfactory bulbectomised (OB) rats. We examined OB-induced changes in cholinergic signalling, as well as AChE, α4-nAChR, and α7-nAChR expression in the hippocampus. The results indicate that abnormal cholinergic signalling in the hippocampus contributes to the development of depression in the OB rat model. This depression may be alleviated following treatment with sarsasapogenin.

We also recommend Trading Suppliers and Manufacturers of Sarsasapogenin (cas 126-19-2). Pls Click Website Link as below: cas 126-19-2 suppliers

Prev:Synthesis and SAR study of novel Sarsasapogenin (cas 126-19-2) derivatives as potent neuroprotective agents and NO production inhibitors
Next:Research paperNovel Sarsasapogenin (cas 126-19-2)-triazolyl hybrids as potential anti-Alzheimer's agents: Design, synthesis and biological evaluation)